Biogen Inc. (NASDAQ:BIIB) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Biogen has a consensus analyst rating of “Moderate Buy”, with 29 analysts covering the stock and an average 1-year price target of about $215.81.
• Several analysts recently raised their price targets on BIIB, including Oppenheimer to $300 and Canaccord Genuity to $245, while maintaining bullish ratings on the shares.
• Biogen reported better-than-expected quarterly results, with EPS of $3.57 versus estimates of $2.95 and revenue of $2.48 billion versus expectations of $2.29 billion, while also highlighting progress in its pipeline and some legal/investigation-related overhangs.

Shares of Biogen Inc. (NASDAQ:BIIB - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twenty-nine analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation, fourteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $215.8077.

A number of equities analysts recently issued reports on BIIB shares. Oppenheimer increased their price objective on Biogen from $275.00 to $300.00 and gave the stock an "outperform" rating in a report on Thursday, May 14th. Rothschild & Co Redburn upped their target price on Biogen from $180.00 to $190.00 in a research report on Thursday, April 30th. Tudor Pickering set a $201.00 price target on Biogen in a research note on Monday, February 9th. Wolfe Research set a $231.00 price target on Biogen in a research note on Monday, February 9th. Finally, Canaccord Genuity Group increased their price target on Biogen from $230.00 to $245.00 and gave the company a "buy" rating in a research note on Wednesday, April 1st.

Hedge Funds Weigh In On Biogen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BIIB. Empowered Funds LLC boosted its stake in Biogen by 64.9% during the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company's stock valued at $965,000 after purchasing an additional 2,777 shares in the last quarter. Focus Partners Wealth boosted its stake in Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company's stock valued at $1,392,000 after purchasing an additional 6,436 shares in the last quarter. Sivia Capital Partners LLC bought a new position in Biogen during the 2nd quarter valued at $216,000. Cerity Partners LLC boosted its stake in Biogen by 15.3% during the 2nd quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company's stock valued at $5,847,000 after purchasing an additional 6,184 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its stake in Biogen by 13.4% during the 2nd quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company's stock valued at $336,000 after purchasing an additional 316 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Biogen Stock Performance

Shares of BIIB stock opened at $195.34 on Friday. Biogen has a 12-month low of $121.05 and a 12-month high of $205.97. The firm has a market capitalization of $28.84 billion, a price-to-earnings ratio of 20.96, a price-to-earnings-growth ratio of 1.72 and a beta of 0.20. The business has a 50 day simple moving average of $187.60 and a 200 day simple moving average of $183.33. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the company posted $3.02 EPS. The business's revenue for the quarter was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities research analysts anticipate that Biogen will post 14.18 EPS for the current year.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen’s salanersen won FDA Breakthrough Therapy Designation for SMA, with early phase 1b data suggesting meaningful motor improvements and a once-yearly dosing profile that could make the therapy stand out commercially. BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
• Positive Sentiment: Biogen also highlighted progress on BIIB115 in post-gene therapy SMA, adding to investor optimism that the company has multiple shots on goal in a key neurodegeneration market. Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth
• Positive Sentiment: Biogen and UCB presented additional data on dapirolizumab pegol in lupus, showing reduced flare rates and lower steroid use, which supports the drug’s potential in a large autoimmune market. UCB and Biogen build steroid-sparing case for lupus drug
• Neutral Sentiment: Biogen is also facing legal overhang after law firms announced investor investigations and fraud-related claims, which could keep sentiment cautious even as pipeline news improves. BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
• Neutral Sentiment: A separate investor alert from Pomerantz also flagged a claims investigation into Biogen, adding another potential risk factor, though it does not yet indicate any formal enforcement action. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.